Using NeuExcell’s neuroregenerative gene therapy platform, the collaboration aims to develop an effective and safe treatment for patients suffering from Huntington’s Disease. Spark Therapeutic’s excellence in R&D and proprietary adeno-associated virus (AAV) vector gene therapy platform may advance the development […]
Read More>>